Table: Takeda Pharma 6-MTH group results (IFRS)

Takeda Pharmaceutical

30/10/2025 06:40

Oct 30 (Reuters)- 
              Takeda Pharmaceutical Co. Ltd. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   6 months ended      6 months ended       Year to 
                  Sep 30, 2025        Sep 30, 2024     Mar 31, 2026 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales             2.22 trln           2.38 trln        4.50 trln  
                   (-6.9 pct)          (+13.4 pct)      (-1.8 pct)  
  Operating          253.56              350.58           400.00    
                   (-27.7 pct)        (+194.0 pct)      (+16.8 pct) 
  Pretax             178.80              255.98           243.00    
                   (-30.1 pct)        (+555.5 pct)      (+38.8 pct) 
  Net                112.44              187.29           153.00    
                   (-40.0 pct)        (+352.8 pct)      (+41.8 pct) 
  EPS Basic         71.57 yen          118.85 yen        97.14 yen  
  EPS Diluted       70.45 yen          117.11 yen                   
  Ann Div                              196.00 yen       200.00 yen  
  -Q2 Div          100.00 yen           98.00 yen                   
  -Q4 Div                               98.00 yen       100.00 yen  
 
  NOTE - Takeda Pharmaceutical Co. Ltd.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4502.T